Malvern, PA, July 19, 2018 — PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for orphan diseases with an initial focus on cardiopulmonary disorders, today announced the appointment of Caroline M. Loewy to its board of directors. Ms. Loewy will serve as Chair of the Audit Committee.
“Caroline has extensive financial, clinical strategy and business development expertise, particularly in rare diseases. We look forward to leveraging these strengths as we advance the clinical development of our orphan therapies,” said Jonathan P. Mow, Chief Executive Officer of PhaseBio. “We are delighted to welcome Caroline to our board of directors.”
Ms. Loewy has more than 25 years of experience in the biotechnology industry, and currently provides strategic business and financial advisory services to life science companies. Ms. Loewy has held numerous executive roles throughout her career, most recently as co-founder, Chief Financial Officer and Chief Business Officer of Achieve Life Sciences, Inc. (acquired by OncoGenex), a company focused on the late-stage development of a smoking cessation compound. Prior to Achieve Life Sciences, Ms. Loewy served as Chief Financial Officer of companies including Tobira Therapeutics, Inc., Corcept Therapeutics, Inc. and Poniard Pharmaceuticals, Inc.
Earlier in her career, Ms. Loewy was Executive Director, Biotechnology Equity Research at Morgan Stanley, and served in roles of increasing responsibility at Prudential Securities, Inc., including Managing Director, Biotechnology Equity Research. She began her career as a financial analyst at BankAmerica Corporation.
Ms. Loewy serves on the boards of directors of Aptose Biosciences, Inc. and CymaBay Therapeutics, Inc. She is a founding board member of the Global Genes Project, a leading rare disease patient advocacy organization, a member of the National Advisory Committee of the Translational Genomics Research Institute’s (TGen) Center for Rare Childhood Disorders and a co-founder of KCNQ2 Cure Alliance, a non-profit advancing research for the rare disease KCNQ2 epileptic encephalopathy. Ms. Loewy holds an MBA and M.S. from Carnegie Mellon University and a B.A. from the University of California, Berkeley.
“PhaseBio’s focus on the development of therapies for the treatment of orphan diseases is within my area of expertise and experience,” said Ms. Loewy. “I look forward to working with the company to build value by strategically and efficiently advancing the clinical development of therapies for patients with unmet medical needs.”
PhaseBio Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of orphan diseases, with an initial focus on cardiopulmonary disorders. The company’s lead development candidate is PB2452, a reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is also leveraging its proprietary elastin-like polypeptide (ELP) biopolymer technology platform to develop therapies with the potential for less-frequent dosing and better patient compliance. PhaseBio’s development candidate based on ELP, PB1046, is a weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA. For more information, please visit www.phasebio.com.
Laura Bagby, 6 Degrees